Shareholders' Equity Share-based Compensation (Details) (USD $)	3 Months Ended		9 Months Ended			3 Months Ended		9 Months Ended				3 Months Ended	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012 Common Stock [Member]	Sep. 30, 2012 Restricted Stock [Member]	Sep. 30, 2011 Restricted Stock [Member]	Sep. 30, 2012 Restricted Stock [Member]	Sep. 30, 2011 Restricted Stock [Member]	Mar. 31, 2012 Restricted Stock [Member]	Mar. 31, 2011 Restricted Stock [Member]	Sep. 30, 2012 Stock Appreciation Rights (SARs) [Member]	Sep. 30, 2012 Stock Appreciation Rights (SARs) [Member]	Sep. 30, 2011 Stock Appreciation Rights (SARs) [Member]	Dec. 31, 2011 Stock Appreciation Rights (SARs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					2,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant					1,805,276
Share-based Compensation Arrangements, Restricted Stock, Outstanding [Roll Forward]
Restricted stock outstanding at beginning of the period								365,506	25,000	454,117	330,500
Restricted stock granted during the period						0	35,006	220,821	358,006
Restricted stock vested during the period						2,917	0	135,127	17,500
Restricted stock outstanding at end of the period						451,200	365,506	451,200	365,506	454,117	330,500
Nonvested restricted stock, fair value remaining to be amortized						$ 3,438		$ 3,438
Stock appreciation rights, exercises in period, number												25,000	31,875
Stock appreciation rights, exercises in period, weighted average exercise price												$ 6.61	$ 6.71
Stock appreciation rights, period increase (decrease)														0
Stock appreciation rights, vested and exercisable, number												27,500	27,500
Stock appreciation rights, vested and exercisable, weighted average exercise price												$ 7.06	$ 7.06
Stock appreciation rights, vested and exercisable, weighted average remaining contractual term													15 months
Stock appreciation rights, fair value of liability remaining												103	103		77
Total share-based compensation expense	$ 490	$ 139	$ 1,410	$ 492